Humulin I Kwikpen (Isophane)

Humulin I Kwikpen is a prefilled, disposable KwikPen containing insulin human (isophane) for subcutaneous injection. It is a suspension formulation of intermediate‑acting insulin, marketed in the European Union. The pen delivers a variable dose as prescribed by a healthcare professional. Humulin I Kwikpen provides a convenient, ready‑to‑use device for patients requiring basal insulin therapy and is indicated for both type 1 and type 2 diabetes mellitus, supplied in a tamper‑evident cartridge.

Humulin I Kwikpen (insulin human isophane) is used as part of a basal insulin regimen to control blood glucose in diabetes.

- For adults with type 1 diabetes mellitus requiring intermediate‑acting insulin. - For adults with type 2 diabetes mellitus when basal insulin is indicated. - As an adjunct to rapid‑acting insulin analogues for a basal‑bolus therapy approach. - In patients who need a stable, long‑duration insulin effect to reduce fasting glucose. - When a prefilled pen device is preferred for ease of administration.

Like all insulin preparations, Humulin I Kwikpen may cause adverse reactions. Reported events are grouped by frequency and severity.

Common: - Hypoglycemia, which may manifest as sweating, tremor, hunger, confusion, or irritability. - Injection‑site reactions such as mild redness, swelling, itching, or bruising. - Lipodystrophy, including localized lipoatrophy or lipohypertrophy at the site of repeated injections. - Gradual weight gain that can accompany improved glycemic control.

Serious: - Severe hypoglycemia that can result in loss of consciousness, seizures, or need for assistance. - Allergic reactions ranging from urticaria and angio‑edema to anaphylactic shock. - Fluid retention or edema that may worsen pre‑existing heart failure. - Persistent hyperglycemia or ketoacidosis indicating possible insulin resistance or dosing issues.

Before using Humulin I Kwikpen, patients and clinicians should consider several safety precautions to minimize risks and ensure appropriate therapy. - Verify the correct insulin type and concentration before each injection. - Rotate injection sites to reduce the risk of lipodystrophy. - Monitor blood glucose regularly, especially when initiating or changing dose. - Adjust doses during periods of illness, surgery, or altered physical activity. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Pregnant or breastfeeding women should consult a healthcare provider, as safety data are limited.

Humulin I Kwikpen can interact with other medicines, affecting glucose control or increasing adverse effects.

Avoid: - Concomitant use of other insulin products or insulin secretagogues without dose adjustment, which may cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms.

Use with caution: - Oral antidiabetic agents (e.g., metformin, sulfonylureas) requiring close glucose monitoring. - Corticosteroids, which can raise blood glucose and may necessitate higher insulin doses. - Thyroid hormones, as hyperthyroidism can increase insulin requirements. - Alcohol, especially in excess, which can unpredictably affect blood glucose levels.